Industry Reports

Custom Research

About

Knowledge Center

Contact

Global Neuromodulation Market Assessment, By Type [External Neuromodulation, Internal Neuromodulation], By Application [Parkinson’s Disease, Failed Back Syndrome, Tremor, Depression, Urinary and Fecal Incontinence, Chronic Pain Management, Dystonia, Migraine, Epilepsy, Others], By Biomaterial [Polymeric Biomaterials, Metallic Biomaterials, Ceramic Biomaterials], By End-user [Hospitals, Specialty Clinics, Others], By Region, Opportunities and Forecast, 2017-2031F

Q: Who are the key players operating in the global neuromodulation market?

The key players operating in the global neuromodulation market are Medtronic PLC, Boston Scientific Corporation, Abbott Laboratories, Nevro Corporation, Synapse Biomedical Inc., Nevro Corporation, Neurosigma Inc., Neuronetics Inc., LivaNova PLC, and Neuropace Inc.

Q: What regions are covered in the final report of the global neuromodulation market?

The final report on the global neuromodulation market covers North America, Europe, South America, Asia-Pacific, and the Middle East and Africa.

Q: What are the major factors influencing the growth of the global neuromodulation market?

The major drivers influencing the global neuromodulation market growth include the increasing emphasis on the development of novel therapeutic solutions and the growing prevalence of Parkinson’s disease.

Q: What is the market size and growth rate of the global neuromodulation market?

The global neuromodulation market was valued at USD 5.23 billion in 2023 and is expected to grow to USD 11.44 billion in 2031F, with a CAGR of 10.28% for the forecast period between 2024 and 2031F.

Global neuromodulation market is expected to witness significant growth over the coming years due to increasing prevalence of different neurological conditions and rising investments towards research and development activities.

Home>Industry Reports>Global Neuromodulation Market Assessment, Opportunities and Forecast, 2017-2031F

Global neuromodulation market is projected to witness a CAGR of 10.28% during the forecast period 2024-2031F, growing from USD 5.23 billion in 2023 to USD 11.44 billion in 2031F. The market's growth is boosted by the increasing prevalence of various chronic neurological conditions, including Parkinson’s Disease, epilepsy, chronic pain, migraine, and others, rising emphasis on developing advanced neuromodulation technologies and increasing awareness about various advantages of neuromodulation therapies.

The increasing prevalence of different neurological conditions is a major global neuromodulation market trend. The rising incidence of individuals suffering from chronic pain, among others, is one of the major factors bolstering the demand for neuromodulation therapies and devices. According to the estimates of the US Pain Foundation, approximately 51.6 million adults, almost 21% of the population of the United States, are living with chronic pain, propelling the requirement for neuromodulation devices as they aid in pain management and treatment of the condition. Using implanted restorative neuromodulation devices re-establishes the strength and stability of the spine by providing continuous contractions to the multifidus muscles, resulting in reduced pain.

The growing efforts by various market players towards introducing advanced and novel therapeutic solutions to enhance patient comfort and convenience is one of the major factors boosting the global neuromodulation market size. For instance, in March 2024, Axonics announced that their Axonics R20 rechargeable sacral neuromodulation (SNM) system received CE-mark approval. The R20 provides patients and physicians with expanded magnetic resonance imaging (MRI) labeling and enhanced programming capabilities. R20 underscores Axonics’ commitment to innovation and provides a significant breakthrough for rechargeable neuromodulation devices.

Such efforts allow the development of neuromodulation devices that support the treatment of diseases and disorders for which neuromodulation was not previously used. In March 2023, GreyMatters's Prism technology became the first neuromodulation system to receive approval from the Food and Drug Administration (FDA) as an adjunct PTSD treatment. GrayMatters aims to use deidentified data collected throughout Prism treatments to develop patient management tools and treatment predictors.

Research and Development Activities Support Global Neuromodulation Market Growth

The growing efforts by various organizations and companies towards research and development activities are expected to support the market expansion in the coming years. Such efforts bolster the development of advanced technologies and products, which are then approved for use by suitable regulatory bodies. For instance, in January 2024, Neurolief’s Relivion received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) as a migraine therapy in Japan. The device uses multi-channel and non-invasive brain neuromodulation technology and stimulates both trigeminal and occipital nerve branches, neural pathways that are responsible for migraine. RelivionMG, which is used for treating acute migraines, received approval from the U.S. FDA.

Research and development activities enhance patient convenience and aid in developing high-quality products to ensure better patient outcomes. They allow the translation of ideas, aiding healthcare professionals in addressing the different requirements of their patients and making therapies and products accessible, affordable, and acceptable. Due to the growing burden of different neurological conditions, including migraine and Parkinson’s, the investments in research and development activities are increasing, thus bolstering product innovation and positively influencing the expansion of the market.

Increasing Prevalence of Neurological Conditions Boosts Global Neuromodulation Market Demand

According to the estimates of the World Health Organization (WHO), more than 50 million people across the globe are living with epilepsy, which is one of the most common neurological diseases. The approved neuromodulation therapies for treating adults with drug-resistant focal epilepsy include responsive neurostimulation, deep brain stimulation of the anterior nucleus of the thalamus, and vagus nerve stimulation.

The rising number of different neurological conditions such as migraine, epilepsy, and chronic pain, coupled with increasing awareness and rate of diagnosis, is propelling the requirement for neuromodulation devices across the globe. This is because treating several disorders relies upon creating focal points or biological and chronic noncurative pharmacologic treatments. The broad therapeutic potential of neuromodulation and ongoing improvements in biotechnology are providing lucrative growth opportunities to the market. Moreover, neuromodulation devices are capable of stimulating responses in conditions where previously they weren’t available, including the cochlear implant, which is used to restore hearing for deaf patients. Thus, as the prevalence of different neurological conditions increases, the demand for neuromodulation devices is expected to rise, supporting the expansion of the market.

North America to Account for Significant Global Neuromodulation Market Share

The strong presence of several leading market players, rising emphasis on developing novel therapeutics solutions, and growing requirement for neuromodulation devices due to the increasing prevalence of neurological disorders are major factors augmenting the market growth in North America. The rising investments by leading market players in research and development activities provide lucrative growth opportunities for the market as these activities support the innovation of products with advanced technologies.

As per the estimates of the American Migraine Foundation, approximately 39 million Americans are living with migraine. Due to the rising prevalence of such conditions, the requirement for different treatment solutions is increasing, including neuromodulation devices. The high rate of adoption of advanced and novel technologies in the region, coupled with increased investments in the biopharmaceutical and pharmaceutical sectors, is further propelling the growth of the market.

Download Free Sample Report

Parkinson’s Disease Accounts for Significant Global Neuromodulation Market Share

The increasing prevalence of Parkinson’s disease in various regions across the globe is providing lucrative growth opportunities to the market. According to the estimates of the Parkinson’s Foundation, approximately 90,000 individuals are diagnosed with Parkinson’s disease every year in the United States. Parkinson’s disease is characterized by various motor symptoms such as postural instability, rigidity, tremors, and bradykinesia. The physiological dysfunction of the condition involves basal ganglia pathways that contribute towards non-motor and motor symptoms, the pathways can be influenced by neural network modulations with the help of magnetic or electrical fields. Deep brain stimulation is often used for treating the condition by applying small pulses of electrical currents at various locations in the brain using implanted electrodes. The stimulations then aid in restoring the circuit balance that had been disrupted by the condition. They alleviate tremors and reduce dyskinesias and stiffness and are highly effective against on and off fluctuations. Thus, bolstering the demand for neuromodulation devices. Additionally, rising efforts towards the development of noninvasive neuromodulation technologies as potential treatments for Parkinson’s disease is expected to provide lucrative growth opportunities to the market in the coming years.

Future Market Scenario (2024 – 2031F)

According to the global neuromodulation market analysis, the market is expected to grow significantly over the forecast period. The growth will be supported by the increase in the number of cases of various neurological diseases such as migraine, rising collaborations between the key players of the market, and growing investments towards research activities by various research institutions across the globe. For instance, the University of Calgary is conducting an interventional study to assess the working of a novel neuromodulation device for acute migraine attacks in children and adolescents. The randomized clinical trial aims to determine the acceptability and feasibility of implementing phase III RCT for treating adolescents and children suffering from acute migraine attacks. The study aims to gather preliminary safety and efficacy data on the utilization of REN and is expected to conclude in August 2024.

Over the coming years, the advancements in the understanding of mechanism of action of stimulation and neuroanatomical networks along with advancements in miniaturization and material sciences will bolster the utilization of neuromodulation devices. The future modulation methods are expected to aim for reduced invasiveness and high specificity.

Report Scope

“Neuromodulation Market Assessment, Opportunities and Forecast, 2017-2031F”, is a comprehensive report by Markets and data, providing in-depth analysis and qualitative and quantitative assessment of the current state of global neuromodulation market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, opportunities, and forecast between 2024 and 2031F. Additionally, the report profiles the leading players in the industry, mentioning their respective market share, business models, competitive intelligence, etc.

Report Attribute	Details
Base Year of the Analysis	2023
Historical Period	2017-2022
Forecast Period	2024-2031F
Projected Growth Rate	CAGR of 10.28% between 2024-2031F
Revenue Forecast in 2031	USD 11.44 billion
Segments Covered	Type, Application, Biomaterial, End-user
Regions Covered	North America, Europe, South America, Asia-Pacific, Middle East and Africa
Key Companies Profiled	Medtronic PLC, Boston Scientific Corporation, Abbott Laboratories, Nevro Corporation, Synapse Biomedical Inc., Nevro Corporation, Neurosigma Inc., Neuronetics Inc., LivaNova PLC, Neuropace Inc.
Customization Scope	15% free report customization with purchase
Pricing and Purchase Options	Avail the customized purchase options to fulfill your precise research needs
Delivery Format	PDF and Excel through email (subject to the license purchased)

In the report, global neuromodulation market has been segmented into the following categories:

By Type
- External Neuromodulation
  - Transcranial Magnetic Stimulator
  - Respiratory Electrical Stimulator
  - Transcutaneous Electrical Nerve Stimulator
- Internal Neuromodulation
  - Spinal Cord Stimulator
  - Vagus Nerve Stimulator
  - Gastric Electrical Stimulator
  - Deep Brain Stimulator
  - Sacral Nerve Stimulator
- By Application
  - Parkinson’s Disease
  - Failed Back Syndrome
  - Tremor
  - Depression
  - Urinary and Fecal Incontinence
  - Chronic Pain Management
  - Dystonia
  - Migraine
  - Epilepsy
  - Others
- By Biomaterial
  - Polymeric Biomaterials
  - Metallic Biomaterials
  - Ceramic Biomaterials
- By End-user
  - Hospitals
  - Specialty Clinics
  - Others
- By Region
  - North America
  - South America
  - Europe
  - Asia-Pacific
  - Middle East and Africa

Key Players Landscape and Outlook

The growth of the market is supported by successful mergers and collaborations and acquisitions that allow companies to expand their customer base and enhance their product portfolio. In September 2023, Boston Scientific Corporation announced that they had successfully acquired Relievant Medsystems, Inc., the medical technology company known for commercializing and developing the Intracept Intraosseous Nerve Ablation System for treating vertebrogenic pain. Relievant Medsystems is expected to witness year over year growth that exceeds 50% in 2024. The acquisition intends to support the expansion of the neuromodulation portfolio of Boston Scientific, allowing them to provide more treatment solutions for patients living with chronic back pain.

Key Players Operating in the Global Neuromodulation Market are:

Medtronic PLC
Boston Scientific Corporation
Abbott Laboratories
Nevro Corporation
Synapse Biomedical Inc.
Nevro Corporation
Neurosigma Inc.
Neuronetics Inc.
LivaNova PLC
Neuropace Inc.

Markets and Data report answers the following questions:

What is the current and future market size of the product/service in question globally or specific to different countries?
How are the markets divided into different product/service segments and the market size and growth of each segment?
What is the market potential of different product segments and their investment case?
How are the markets predicted to develop in the future and what factors will drive or inhibit growth?
What is the business environment and regulatory landscape specific to the product/service?

If you can't find what you're searching for or have any custom requirements for global neuromodulation market, you may approach our team at info@marketsandata.com.

Table of Contents

1. Research Methodology

2. Project Scope and Definitions

3. Executive Summary

4. Global Neuromodulation Market Outlook, 2017-2031F

4.1. Market Size & Forecast

4.1.1.By Value

4.1.2.By Volume

4.2. By Type

4.2.1.External Neuromodulation

4.2.1.1. Transcranial Magnetic Stimulator

4.2.1.2. Respiratory Electrical Stimulator

4.2.1.3. Transcutaneous Electrical Nerve Stimulator

4.2.2.Internal Neuromodulation

4.2.2.1. Spinal Cord Stimulator

4.2.2.2. Vagus Nerve Stimulator

4.2.2.3. Gastric Electrical Stimulator

4.2.2.4. Deep Brain Stimulator

4.2.2.5. Sacral Nerve Stimulator

4.3. By Application

4.3.1.Parkinson’s Disease

4.3.2.Failed Back Syndrome

4.3.3.Tremor

4.3.4.Depression

4.3.5.Urinary and Fecal Incontinence

4.3.6.Chronic Pain Management

4.3.7.Dystonia

4.3.8.Migraine

4.3.9.Epilepsy

4.3.10. Others

4.4. By Biomaterial

4.4.1.Polymeric Biomaterials

4.4.2.Metallic Biomaterials

4.4.3.Ceramic Biomaterials

4.5. By End-user

4.5.1.Hospitals

4.5.2.Specialty Clinics

4.5.3.Others

4.6. By Region

4.6.1.North America

4.6.2.South America

4.6.3.Europe

4.6.4.Asia-Pacific

4.6.5.Middle East and Africa

4.7. By Company Market Share (%), 2023

5. Global Neuromodulation Market Outlook, By Region, 2017-2031F

5.1. North America*

5.1.1.Market Size & Forecast

5.1.1.1. By Value

5.1.1.2. By Volume

5.1.2.By Type

5.1.2.1. External Neuromodulation

5.1.2.1.1. Transcranial Magnetic Stimulator

5.1.2.1.2. Respiratory Electrical Stimulator

5.1.2.1.3. Transcutaneous Electrical Nerve Stimulator

5.1.2.2. Internal Neuromodulation

5.1.2.2.1. Spinal Cord Stimulator

5.1.2.2.2. Vagus Nerve Stimulator

5.1.2.2.3. Gastric Electrical Stimulator

5.1.2.2.4. Deep Brain Stimulator

5.1.2.2.5. Sacral Nerve Stimulator

5.1.3.By Application

5.1.3.1. Parkinson’s Disease

5.1.3.2. Failed Back Syndrome

5.1.3.3. Tremor

5.1.3.4. Depression

5.1.3.5. Urinary and Fecal Incontinence

5.1.3.6. Chronic Pain Management

5.1.3.7. Dystonia

5.1.3.8. Migraine

5.1.3.9. Epilepsy

5.1.3.10. Others

5.1.4.By Biomaterial

5.1.4.1. Polymeric Biomaterials

5.1.4.2. Metallic Biomaterials

5.1.4.3. Ceramic Biomaterials

5.1.5.By End-user

5.1.5.1. Hospitals

5.1.5.2. Specialty Clinics

5.1.5.3. Others

5.1.6.United States*

5.1.6.1. Market Size & Forecast

5.1.6.1.1. By Value

5.1.6.1.2. By Volume

5.1.6.2. By Type

5.1.6.2.1. External Neuromodulation

5.1.6.2.1.1. Transcranial Magnetic Stimulator

5.1.6.2.1.2. Respiratory Electrical Stimulator

5.1.6.2.1.3. Transcutaneous Electrical Nerve Stimulator

5.1.6.2.2. Internal Neuromodulation

5.1.6.2.2.1. Spinal Cord Stimulator

5.1.6.2.2.2. Vagus Nerve Stimulator

5.1.6.2.2.3. Gastric Electrical Stimulator

5.1.6.2.2.4. Deep Brain Stimulator

5.1.6.2.2.5. Sacral Nerve Stimulator

5.1.6.3. By Application

5.1.6.3.1. Parkinson’s Disease

5.1.6.3.2. Failed Back Syndrome

5.1.6.3.3. Tremor

5.1.6.3.4. Depression

5.1.6.3.5. Urinary and Fecal Incontinence

5.1.6.3.6. Chronic Pain Management

5.1.6.3.7. Dystonia

5.1.6.3.8. Migraine

5.1.6.3.9. Epilepsy

5.1.6.3.10. Others

5.1.6.4. By Biomaterial

5.1.6.4.1. Polymeric Biomaterials

5.1.6.4.2. Metallic Biomaterials

5.1.6.4.3. Ceramic Biomaterials

5.1.6.5. By End-user

5.1.6.5.1. Hospitals

5.1.6.5.2. Specialty Clinics

5.1.6.5.3. Others

5.1.7.Canada

5.1.8.Mexico

*All segments will be provided for all regions and countries covered

5.2. Europe

5.2.1.Germany

5.2.2.France

5.2.3.Italy

5.2.4.United Kingdom

5.2.5.Russia

5.2.6.Netherlands

5.2.7.Spain

5.2.8.Turkey

5.2.9.Poland

5.3. Asia-Pacific

5.3.1.India

5.3.2.China

5.3.3.Japan

5.3.4.Australia

5.3.5.Vietnam

5.3.6.South Korea

5.3.7.Indonesia

5.3.8.Philippines

5.4. South America

5.4.1.Brazil

5.4.2.Argentina

5.5. Middle East and Africa

5.5.1.Saudi Arabia

5.5.2.UAE

5.5.3.South Africa

6. Market Mapping, 2023

6.1. By Type

6.2. By Application

6.3. By Biomaterial

6.4. By End-user

6.5. By Region

7. Macro Environment and Industry Structure

7.1. Supply Demand Analysis

7.2. Import Export Analysis

7.3. Value Chain Analysis

7.4. PESTEL Analysis

7.4.1. Political Factors

7.4.2. Economic System

7.4.3. Social Implications

7.4.4. Technological Advancements

7.4.5. Environmental Impacts

7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)

7.5. Porter’s Five Forces Analysis

7.5.1. Supplier Power

7.5.2. Buyer Power

7.5.3. Substitution Threat

7.5.4. Threat from New Entrant

7.5.5. Competitive Rivalry

8. Market Dynamics

8.1. Growth Drivers

8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

9.1. Clinical Trials

9.2. Patent Landscape

9.3. Regulatory Approvals

9.4. Innovations/Emerging Technologies

10. Key Players Landscape

10.1. Competition Matrix of Top Five Market Leaders

10.2. Market Revenue Analysis of Top Five Market Leaders (By Value, 2023)

10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)

10.4. SWOT Analysis (For Five Market Players)

10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

13.1. Medtronic PLC

13.1.1. Company Details

13.1.2. Key Management Personnel

13.1.3. Products and Services

13.1.4. Financials (As reported)

13.1.5. Key Market Focus and Geographical Presence

13.1.6. Recent Developments

13.2. Boston Scientific Corporation

13.3. Abbott Laboratories

13.4. Nevro Corporation

13.5. Synapse Biomedical Inc.

13.6. Nevro Corporation

13.7. Neurosigma Inc.

13.8. Neuronetics Inc.

13.9. LivaNova PLC

13.10. Neuropace Inc.

*Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

14. Strategic Recommendations

15. About Us and Disclaimer

List of Figures

Figure 1. Global Neuromodulation Market, By Value, In USD Billion, 2017-2031F

Figure 2. Global Neuromodulation Market, By Volume, In Million Units, 2017-2031F

Figure 3. Global Neuromodulation Market Share (%), By Type, 2017-2031F

Figure 4. Global Neuromodulation Market Share (%), By Application, 2017-2031F

Figure 5. Global Neuromodulation Market Share (%), By Biomaterial, 2017-2031F

Figure 6. Global Neuromodulation Market Share (%), By End-user, 2017-2031F

Figure 7. Global Neuromodulation Market Share (%), By Region, 2017-2031F

Figure 8. North America Neuromodulation Market, By Value, In USD Billion, 2017-2031F

Figure 9. North America Neuromodulation Market, By Volume, In Million Units, 2017-2031F

Figure 10. North America Neuromodulation Market Share (%), By Type, 2017-2031F

Figure 11. North America Neuromodulation Market Share (%), By Application, 2017-2031F

Figure 12. North America Neuromodulation Market Share (%), By Biomaterial, 2017-2031F

Figure 13. North America Neuromodulation Market Share (%), By End-user, 2017-2031F

Figure 14. North America Neuromodulation Market Share (%), By Country, 2017-2031F

Figure 15. United States Neuromodulation Market, By Value, In USD Billion, 2017-2031F

Figure 16. United States Neuromodulation Market, By Volume, In Million Units, 2017-2031F

Figure 17. United States Neuromodulation Market Share (%), By Type, 2017-2031F

Figure 18. United States Neuromodulation Market Share (%), By Application, 2017-2031F

Figure 19. United States Neuromodulation Market Share (%), By Biomaterial, 2017-2031F

Figure 20. United States Neuromodulation Market Share (%), By End-user, 2017-2031F

Figure 21. Canada Neuromodulation Market, By Value, In USD Billion, 2017-2031F

Figure 22. Canada Neuromodulation Market, By Volume, In Million Units, 2017-2031F

Figure 23. Canada Neuromodulation Market Share (%), By Type, 2017-2031F

Figure 24. Canada Neuromodulation Market Share (%), By Application, 2017-2031F

Figure 25. Canada Neuromodulation Market Share (%), By Biomaterial, 2017-2031F

Figure 26. Canada Neuromodulation Market Share (%), By End-user, 2017-2031F

Figure 27. Mexico Neuromodulation Market, By Value, In USD Billion, 2017-2031F

Figure 28. Mexico Neuromodulation Market, By Volume, In Million Units, 2017-2031F

Figure 29. Mexico Neuromodulation Market Share (%), By Type, 2017-2031F

Figure 30. Mexico Neuromodulation Market Share (%), By Application, 2017-2031F

Figure 31. Mexico Neuromodulation Market Share (%), By Biomaterial, 2017-2031F

Figure 32. Mexico Neuromodulation Market Share (%), By End-user, 2017-2031F

Figure 33. Europe Neuromodulation Market, By Value, In USD Billion, 2017-2031F

Figure 34. Europe Neuromodulation Market, By Volume, In Million Units, 2017-2031F

Figure 35. Europe Neuromodulation Market Share (%), By Type, 2017-2031F

Figure 36. Europe Neuromodulation Market Share (%), By Application, 2017-2031F

Figure 37. Europe Neuromodulation Market Share (%), By Biomaterial, 2017-2031F

Figure 38. Europe Neuromodulation Market Share (%), By End-user, 2017-2031F

Figure 39. Europe Neuromodulation Market Share (%), By Country, 2017-2031F

Figure 40. Germany Neuromodulation Market, By Value, In USD Billion, 2017-2031F

Figure 41. Germany Neuromodulation Market, By Volume, In Million Units, 2017-2031F

Figure 42. Germany Neuromodulation Market Share (%), By Type, 2017-2031F

Figure 43. Germany Neuromodulation Market Share (%), By Application, 2017-2031F

Figure 44. Germany Neuromodulation Market Share (%), By Biomaterial, 2017-2031F

Figure 45. Germany Neuromodulation Market Share (%), By End-user, 2017-2031F

Figure 46. France Neuromodulation Market, By Value, In USD Billion, 2017-2031F

Figure 47. France Neuromodulation Market, By Volume, In Million Units, 2017-2031F

Figure 48. France Neuromodulation Market Share (%), By Type, 2017-2031F

Figure 49. France Neuromodulation Market Share (%), By Application, 2017-2031F

Figure 50. France Neuromodulation Market Share (%), By Biomaterial, 2017-2031F

Figure 51. France Neuromodulation Market Share (%), By End-user, 2017-2031F

Figure 52. Italy Neuromodulation Market, By Value, In USD Billion, 2017-2031F

Figure 53. Italy Neuromodulation Market, By Volume, In Million Units, 2017-2031F

Figure 54. Italy Neuromodulation Market Share (%), By Type, 2017-2031F

Figure 55. Italy Neuromodulation Market Share (%), By Application, 2017-2031F

Figure 56. Italy Neuromodulation Market Share (%), By Biomaterial, 2017-2031F

Figure 57. Italy Neuromodulation Market Share (%), By End-user, 2017-2031F

Figure 58. United Kingdom Neuromodulation Market, By Value, In USD Billion, 2017-2031F

Figure 59. United Kingdom Neuromodulation Market, By Volume, In Million Units, 2017-2031F

Figure 60. United Kingdom Neuromodulation Market Share (%), By Type, 2017-2031F

Figure 61. United Kingdom Neuromodulation Market Share (%), By Application, 2017-2031F

Figure 62. United Kingdom Neuromodulation Market Share (%), By Biomaterial, 2017-2031F

Figure 63. United Kingdom Neuromodulation Market Share (%), By End-user, 2017-2031F

Figure 64. Russia Neuromodulation Market, By Value, In USD Billion, 2017-2031F

Figure 65. Russia Neuromodulation Market, By Volume, In Million Units, 2017-2031F

Figure 66. Russia Neuromodulation Market Share (%), By Type, 2017-2031F

Figure 67. Russia Neuromodulation Market Share (%), By Application, 2017-2031F

Figure 68. Russia Neuromodulation Market Share (%), By Biomaterial, 2017-2031F

Figure 69. Russia Neuromodulation Market Share (%), By End-user, 2017-2031F

Figure 70. Netherlands Neuromodulation Market, By Value, In USD Billion, 2017-2031F

Figure 71. Netherlands Neuromodulation Market, By Volume, In Million Units, 2017-2031F

Figure 72. Netherlands Neuromodulation Market Share (%), By Type, 2017-2031F

Figure 73. Netherlands Neuromodulation Market Share (%), By Application, 2017-2031F

Figure 74. Netherlands Neuromodulation Market Share (%), By Biomaterial, 2017-2031F

Figure 75. Netherlands Neuromodulation Market Share (%), By End-user, 2017-2031F

Figure 76. Spain Neuromodulation Market, By Value, In USD Billion, 2017-2031F

Figure 77. Spain Neuromodulation Market, By Volume, In Million Units, 2017-2031F

Figure 78. Spain Neuromodulation Market Share (%), By Type, 2017-2031F

Figure 79. Spain Neuromodulation Market Share (%), By Application, 2017-2031F

Figure 80. Spain Neuromodulation Market Share (%), By Biomaterial, 2017-2031F

Figure 81. Spain Neuromodulation Market Share (%), By End-user, 2017-2031F

Figure 82. Turkey Neuromodulation Market, By Value, In USD Billion, 2017-2031F

Figure 83. Turkey Neuromodulation Market, By Volume, In Million Units, 2017-2031F

Figure 84. Turkey Neuromodulation Market Share (%), By Type, 2017-2031F

Figure 85. Turkey Neuromodulation Market Share (%), By Application, 2017-2031F

Figure 86. Turkey Neuromodulation Market Share (%), By Biomaterial, 2017-2031F

Figure 87. Turkey Neuromodulation Market Share (%), By End-user, 2017-2031F

Figure 88. Poland Neuromodulation Market, By Value, In USD Billion, 2017-2031F

Figure 89. Poland Neuromodulation Market, By Volume, In Million Units, 2017-2031F

Figure 90. Poland Neuromodulation Market Share (%), By Type, 2017-2031F

Figure 91. Poland Neuromodulation Market Share (%), By Application, 2017-2031F

Figure 92. Poland Neuromodulation Market Share (%), By Biomaterial, 2017-2031F

Figure 93. Poland Neuromodulation Market Share (%), By End-user, 2017-2031F

Figure 94. South America Neuromodulation Market, By Value, In USD Billion, 2017-2031F

Figure 95. South America Neuromodulation Market, By Volume, In Million Units, 2017-2031F

Figure 96. South America Neuromodulation Market Share (%), By Type, 2017-2031F

Figure 97. South America Neuromodulation Market Share (%), By Application, 2017-2031F

Figure 98. South America Neuromodulation Market Share (%), By Biomaterial, 2017-2031F

Figure 99. South America Neuromodulation Market Share (%), By End-user, 2017-2031F

Figure 100. South America Neuromodulation Market Share (%), By Country, 2017-2031F

Figure 101. Brazil Neuromodulation Market, By Value, In USD Billion, 2017-2031F

Figure 102. Brazil Neuromodulation Market, By Volume, In Million Units, 2017-2031F

Figure 103. Brazil Neuromodulation Market Share (%), By Type, 2017-2031F

Figure 104. Brazil Neuromodulation Market Share (%), By Application, 2017-2031F

Figure 105. Brazil Neuromodulation Market Share (%), By Biomaterial, 2017-2031F

Figure 106. Brazil Neuromodulation Market Share (%), By End-user, 2017-2031F

Figure 107. Argentina Neuromodulation Market, By Value, In USD Billion, 2017-2031F

Figure 108. Argentina Neuromodulation Market, By Volume, In Million Units, 2017-2031F

Figure 109. Argentina Neuromodulation Market Share (%), By Type, 2017-2031F

Figure 110. Argentina Neuromodulation Market Share (%), By Application, 2017-2031F

Figure 111. Argentina Neuromodulation Market Share (%), By Biomaterial, 2017-2031F

Figure 112. Argentina Neuromodulation Market Share (%), By End-user, 2017-2031F

Figure 113. Asia-Pacific Neuromodulation Market, By Value, In USD Billion, 2017-2031F

Figure 114. Asia-Pacific Neuromodulation Market, By Volume, In Million Units, 2017-2031F

Figure 115. Asia-Pacific Neuromodulation Market Share (%), By Type, 2017-2031F

Figure 116. Asia-Pacific Neuromodulation Market Share (%), By Application, 2017-2031F

Figure 117. Asia-Pacific Neuromodulation Market Share (%), By Biomaterial, 2017-2031F

Figure 118. Asia-Pacific Neuromodulation Market Share (%), By End-user, 2017-2031F

Figure 119. Asia-Pacific Neuromodulation Market Share (%), By Country, 2017-2031F

Figure 120. India Neuromodulation Market, By Value, In USD Billion, 2017-2031F

Figure 121. India Neuromodulation Market, By Volume, In Million Units, 2017-2031F

Figure 122. India Neuromodulation Market Share (%), By Type, 2017-2031F

Figure 123. India Neuromodulation Market Share (%), By Application, 2017-2031F

Figure 124. India Neuromodulation Market Share (%), By Biomaterial, 2017-2031F

Figure 125. India Neuromodulation Market Share (%), By End-user, 2017-2031F

Figure 126. China Neuromodulation Market, By Value, In USD Billion, 2017-2031F

Figure 127. China Neuromodulation Market, By Volume, In Million Units, 2017-2031F

Figure 128. China Neuromodulation Market Share (%), By Type, 2017-2031F

Figure 129. China Neuromodulation Market Share (%), By Application, 2017-2031F

Figure 130. China Neuromodulation Market Share (%), By Biomaterial, 2017-2031F

Figure 131. China Neuromodulation Market Share (%), By End-user, 2017-2031F

Figure 132. Japan Neuromodulation Market, By Value, In USD Billion, 2017-2031F

Figure 133. Japan Neuromodulation Market, By Volume, In Million Units, 2017-2031F

Figure 134. Japan Neuromodulation Market Share (%), By Type, 2017-2031F

Figure 135. Japan Neuromodulation Market Share (%), By Application, 2017-2031F

Figure 136. Japan Neuromodulation Market Share (%), By Biomaterial, 2017-2031F

Figure 137. Japan Neuromodulation Market Share (%), By End-user, 2017-2031F

Figure 138. Australia Neuromodulation Market, By Value, In USD Billion, 2017-2031F

Figure 139. Australia Neuromodulation Market, By Volume, In Million Units, 2017-2031F

Figure 140. Australia Neuromodulation Market Share (%), By Type, 2017-2031F

Figure 141. Australia Neuromodulation Market Share (%), By Application, 2017-2031F

Figure 142. Australia Neuromodulation Market Share (%), By Biomaterial, 2017-2031F

Figure 143. Australia Neuromodulation Market Share (%), By End-user, 2017-2031F

Figure 144. Vietnam Neuromodulation Market, By Value, In USD Billion, 2017-2031F

Figure 145. Vietnam Neuromodulation Market, By Volume, In Million Units, 2017-2031F

Figure 146. Vietnam Neuromodulation Market Share (%), By Type, 2017-2031F

Figure 147. Vietnam Neuromodulation Market Share (%), By Application, 2017-2031F

Figure 148. Vietnam Neuromodulation Market Share (%), By Biomaterial, 2017-2031F

Figure 149. Vietnam Neuromodulation Market Share (%), By End-user, 2017-2031F

Figure 150. South Korea Neuromodulation Market, By Value, In USD Billion, 2017-2031F

Figure 151. South Korea Neuromodulation Market, By Volume, In Million Units, 2017-2031F

Figure 152. South Korea Neuromodulation Market Share (%), By Type, 2017-2031F

Figure 153. South Korea Neuromodulation Market Share (%), By Application, 2017-2031F

Figure 154. South Korea Neuromodulation Market Share (%), By Biomaterial, 2017-2031F

Figure 155. South Korea Neuromodulation Market Share (%), By End-user, 2017-2031F

Figure 156. Indonesia Neuromodulation Market, By Value, In USD Billion, 2017-2031F

Figure 157. Indonesia Neuromodulation Market, By Volume, In Million Units, 2017-2031F

Figure 158. Indonesia Neuromodulation Market Share (%), By Type, 2017-2031F

Figure 159. Indonesia Neuromodulation Market Share (%), By Application, 2017-2031F

Figure 160. Indonesia Neuromodulation Market Share (%), By Biomaterial, 2017-2031F

Figure 161. Indonesia Neuromodulation Market Share (%), By End-user, 2017-2031F

Figure 162. Philippines Neuromodulation Market, By Value, In USD Billion, 2017-2031F

Figure 163. Philippines Neuromodulation Market, By Volume, In Million Units, 2017-2031F

Figure 164. Philippines Neuromodulation Market Share (%), By Type, 2017-2031F

Figure 165. Philippines Neuromodulation Market Share (%), By Application, 2017-2031F

Figure 166. Philippines Neuromodulation Market Share (%), By Biomaterial, 2017-2031F

Figure 167. Philippines Neuromodulation Market Share (%), By End-user, 2017-2031F

Figure 168. Middle East & Africa Neuromodulation Market, By Value, In USD Billion, 2017-2031F

Figure 169. Middle East & Africa Neuromodulation Market, By Volume, In Million Units, 2017-2031F

Figure 170. Middle East & Africa Neuromodulation Market Share (%), By Type, 2017-2031F

Figure 171. Middle East & Africa Neuromodulation Market Share (%), By Application, 2017-2031F

Figure 172. Middle East & Africa Neuromodulation Market Share (%), By Biomaterial, 2017-2031F

Figure 173. Middle East & Africa Neuromodulation Market Share (%), By End-user, 2017-2031F

Figure 174. Middle East & Africa Neuromodulation Market Share (%), By Country, 2017-2031F

Figure 175. Saudi Arabia Neuromodulation Market, By Value, In USD Billion, 2017-2031F

Figure 176. Saudi Arabia Neuromodulation Market, By Volume, In Million Units, 2017-2031F

Figure 177. Saudi Arabia Neuromodulation Market Share (%), By Type, 2017-2031F

Figure 178. Saudi Arabia Neuromodulation Market Share (%), By Application, 2017-2031F

Figure 179. Saudi Arabia Neuromodulation Market Share (%), By Biomaterial, 2017-2031F

Figure 180. Saudi Arabia Neuromodulation Market Share (%), By End-user, 2017-2031F

Figure 181. UAE Neuromodulation Market, By Value, In USD Billion, 2017-2031F

Figure 182. UAE Neuromodulation Market, By Volume, In Million Units, 2017-2031F

Figure 183. UAE Neuromodulation Market Share (%), By Type, 2017-2031F

Figure 184. UAE Neuromodulation Market Share (%), By Application, 2017-2031F

Figure 185. UAE Neuromodulation Market Share (%), By Biomaterial, 2017-2031F

Figure 186. UAE Neuromodulation Market Share (%), By End-user, 2017-2031F

Figure 187. South Africa Neuromodulation Market, By Value, In USD Billion, 2017-2031F

Figure 188. South Africa Neuromodulation Market, By Volume, In Million Units, 2017-2031F

Figure 189. South Africa Neuromodulation Market Share (%), By Type, 2017-2031F

Figure 190. South Africa Neuromodulation Market Share (%), By Application, 2017-2031F

Figure 191. South Africa Neuromodulation Market Share (%), By Biomaterial, 2017-2031F

Figure 192. South Africa Neuromodulation Market Share (%), By End-user, 2017-2031F

Figure 193. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2023

Figure 194. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023

Figure 195. By Biomaterial Map-Market Size (USD Billion) & Growth Rate (%), 2023

Figure 196. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023

Figure 197. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

List of Tables

Table 1. Pricing Analysis of Products from Key Players

Table 2. Competition Matrix of Top 5 Market Leaders

Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)

Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

Frequently Asked Questions

Who are the key players operating in the global neuromodulation market?

What regions are covered in the final report of the global neuromodulation market?

What are the major factors influencing the growth of the global neuromodulation market?

What is the market size and growth rate of the global neuromodulation market?

See Related Reports

View ALL

Global Optical Imaging Market Assessment, Opportunities and Forecast, 2017-2031F

The optical imaging market is expected to grow rapidly because of increasing demand for non-invasive diagnostic methods.....Read More

Published on

July 2024

4,500

Global Pharmaceutical Gelatin Market Assessment, Opportunities and Forecast, 2017-2031F

The pharmaceutical gelatin market is expected to grow because of an increased focus on technological advancements and the increasing popularity of gelatin-based soft gels and hard gelatin capsules.....Read More

Published on

July 2024

4,500

Global Medical Radiation Detection Market Assessment, Opportunities and Forecast, 2017-2031F

The medical radiation detection market is expected to grow due to the rising numbers of imaging procedures, rising cancer cases, technological advancements, medical tourism, and government initiatives.....Read More

Published on

July 2024

4,500

Global Enteral Feeding Devices Market Assessment, Opportunities and Forecast, 2017-2031F

Global enteral feeding devices market is expected to experience significant growth over the forecast period owing to the expansion of the geriatric population and rising prevalence of chronic health conditions such as diabetes and cancer.....Read More

Published on

July 2024

4,500

Purchase Options

USD ($)